Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALBUPHINE vs CEDILANID-D
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.
Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Heart failure,Atrial fibrillation,Atrial flutter
10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.
0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.
Terminal elimination half-life is 5 hours; clinically, in hepatic impairment or elderly, half-life may be prolonged up to 8-10 hours.
Terminal elimination half-life is 36-48 hours in patients with normal renal function; prolonged to >100 hours in severe renal impairment, requiring dose adjustment.
Hepatic metabolism primarily via glucuronidation and oxidative pathways; minor involvement of CYP450 enzymes.
Hepatic (minor); primarily renally excreted unchanged.
Primarily hepatic metabolism; <5% excreted unchanged in urine; about 70% excreted in feces via biliary elimination.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 30-40%, with enterohepatic circulation present.
Approximately 50% bound to plasma proteins, primarily albumin.
25-30% bound to plasma albumin.
2.3 L/kg; indicates extensive tissue distribution, consistent with moderate lipophilicity.
6-10 L/kg; large Vd indicates extensive tissue distribution and high cardiac tissue affinity.
Intravenous: 100%; Intramuscular: approximately 80%; Oral: negligible (<20%) due to extensive first-pass metabolism.
Oral: 70-80%; IV: 100%.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours; Cr Cl <30 m L/min: administer 50% of normal dose every 8 hours.
GFR <50 m L/min: reduce dose by 50% or extend dosing interval to every 36-48 hours. GFR <10 m L/min: avoid use or reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or use alternative.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Digitalizing dose: 0.01-0.02 mg/kg IV or IM, given in divided doses over 24 hours. Maintenance: 10-20% of digitalizing dose daily. Not recommended for neonates due to prolonged half-life.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
Reduce dose by 25-50% due to decreased renal function and increased sensitivity. Monitor serum levels and renal function closely.
Risk of respiratory depression, particularly in opioid-naive patients; risk of dependence and abuse; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Can cause potentially fatal arrhythmias; use only when clearly indicated and monitor serum levels.
Respiratory depression may occur, especially in elderly, cachectic, or debilitated patients,Avoid use in patients with head injury or increased intracranial pressure,May precipitate withdrawal in opioid-dependent patients,Hypotension, biliary tract spasm, and seizure risk
Narrow therapeutic index; toxicity risk increased with hypokalemia, hypomagnesemia, hypercalcemia, renal impairment; monitor ECG and drug levels.
Hypersensitivity to nalbuphine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Suspected or known gastrointestinal obstruction
Ventricular fibrillation, digitalis toxicity, hypersensitivity, AV block (unless pacemaker present), Wolff-Parkinson-White syndrome.
No significant food-drug interactions. Avoid alcohol and grapefruit juice as they may enhance CNS depression.
Avoid licorice, which can cause hypokalemia. Maintain consistent intake of potassium-rich foods (bananas, oranges) to avoid fluctuations. No known significant food interactions beyond electrolyte effects.
FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS) including irritability, hypertonia, tremors, poor feeding. Use only if benefit outweighs risk.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avoids if possible.
Excreted in human milk in low concentrations (M/P ratio ~0.6). Relative infant dose estimated 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation and poor feeding. American Academy of Pediatrics considers compatible with breastfeeding with caution.
Deslanoside is excreted in breast milk; estimated infant dose 0.1-0.5% of maternal weight-adjusted dose; M/P ratio not well defined. Monitor infant for bradycardia, feeding difficulties; benefit likely outweighs risk.
No specific dose adjustments recommended for pregnancy. Increased clearance and volume of distribution in third trimester may potentially reduce efficacy; titrate to effect. Avoid in prolonged labor due to risk of fetal bradycardia.
Increased renal clearance in pregnancy may require higher doses; monitor serum drug levels and adjust accordingly. Reduced dosing in third trimester may be needed due to volume expansion.
Nalbuphine is a mixed agonist-antagonist opioid with a ceiling effect for respiratory depression, making it safer than pure agonists. It can precipitate withdrawal in opioid-dependent patients. Monitor for sedation and hypotension. Reversal with naloxone may be less effective. Use with caution in hepatic impairment. Not recommended for chronic pain due to psychotomimetic effects.
Cedilanid-D (deslanoside) is a rapidly acting parenteral digitalis glycoside. Use with extreme caution in renal impairment due to reduced clearance. Monitor serum potassium and magnesium; hypokalemia and hypomagnesemia potentiate toxicity. Administer slow IV push over 5 minutes to avoid arrhythmias. Therapeutic drug monitoring less common due to short half-life of 33 hours. Contraindicated in ventricular tachycardia and AV block (unless due to atrial fibrillation).
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sleep aids) as they can increase dizziness and drowsiness.,Do not drive or operate heavy machinery until you know how nalbuphine affects you.,Report any signs of withdrawal (e.g., restlessness, tearing, runny nose, yawning, sweating) if you have been taking other opioids.,Seek emergency care if you experience trouble breathing, severe dizziness, or hallucinations.,Do not stop abruptly; tapering may be needed to avoid withdrawal symptoms.
Take exactly as prescribed; do not double doses.,Report symptoms of toxicity: nausea, vomiting, visual disturbances (yellow-green halos), irregular heartbeat.,Avoid over-the-counter medications without consulting doctor.,Maintain consistent potassium intake; avoid high-potassium foods or supplements unless advised.,Monitor daily weight and report rapid weight gain or edema.
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALBUPHINE vs CEDILANID-D, answered by our medical review team.
NALBUPHINE is a Opioid Agonist-Antagonist that works by Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.. CEDILANID-D is a Cardiac Glycoside that works by Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALBUPHINE and CEDILANID-D depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALBUPHINE is: 10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.. The standard adult dose of CEDILANID-D is: 0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALBUPHINE and CEDILANID-D in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALBUPHINE is classified as Category A/B. FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioi. CEDILANID-D is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal risk. Second/third trimester: Risk of fetal bradycardia, cardiac glycoside toxicity; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.